All In Biotech

Drug Trial Radar · NCT04700423

Efficacy and Safety of MOX/ALB vs. IVM/ALB Co-administration

Efficacy and Safety of Moxidectin and Albendazole Compared to Ivermectin and Albendazole Co-administration in Adolescents Infected With Trichuris Trichiura: a Randomized Controlled Trial

Last checked: Nov 19, 2026Latest source record: Dec 5, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 536 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

536

Actual

Start

Mar 1, 2021

Primary completion

Aug 18, 2021

Study completion Sep 22, 2021

Sponsor

Lead sponsor
Jennifer KeiserAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Public Health Laboratory Ivo de Carneri
First posted
Jan 7, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this randomized controlled trial is to provide evidence on the efficacy and safety of co-administered moxidectin and albendazole compared to co-administered ivermectin and albendazole, and to assess the efficacy of the drug combinations compared to monotherapies in adolescents aged 12-19 years against infection with T. trichiura. The efficacy of the different treatments will be determined 14-21 days, 5-6 weeks and 3 months post-treatment. Two fecal samples will be collected at each time-point assessment. The geometric mean based egg reduction rate (ERR) of T. trichiura egg counts will be assessed by Kato-Katz microscopy pre-treatment and 14-21 days post-treatment. This trial will be conducted as a school-based study on Pemba Island (Zanzibar, Tanzania).

Conditions

  • Trichuriasis
  • Ascariasis
  • Hookworm Infections
  • Helminthes; Infestation, Intestinal

Interventions

  • moxidectin (8 mg) / albendazole (400 mg)Drug

    Combination therapy of moxidectin (8 mg using 2 mg tablets) plus albendazole (Zentel®, 400 mg, single tablet) administered orally at day 0

  • ivermectin (200 µg/kg) / albendazole (400 mg)Drug

    Combination therapy of ivermectin ((200 µg/kg), 3 mg tablet) plus albendazole (Zentel®, 400 mg, single tablet) administered orally at day 0

  • ALBENDAZOLE 400 Mg ORAL TABLET [ZENTEL]Drug

    Monotherapy of albendazole (Zentel®, 400 mg, single tablet) administered orally at day 0

  • ivermectin (200 µg/kg)Drug

    Monotherapy of ivermectin ((200 µg/kg), 3 mg tablet) administered orally at day 0

  • moxidectin (8 mg)Drug

    Monotherapy of moxidectin (8 mg, using 2 mg tablets) administered orally at day 0

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Egg Reduction Rate Against T. TrichiuraTime frame: 14-21 day post-treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Public Health Laboratory Ivo de Carneri

    Chake Chake, Pemba, Tanzania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.